

October 30, 2019

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C1, 'G' Block, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051.

BSE Limited  
Corporate Relationship Department Floor  
25, P.J. Towers  
Dalal Street  
Mumbai 400 001.

**Symbol: RPGLIFE**

**Scrip code: 532983**

Dear Sirs,

**Sub: Unaudited Financial Results for the quarter and half year ended September 30, 2019**

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter and half year ended September 30, 2019 which were approved by the Board of Directors of the Company, at its meeting held on October 30, 2019 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 12:00 noon and concluded at 4:00 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited

  
Rajesh Shirambekar  
Head – Legal & Company Secretary



Encl: as above

# BSR & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011  
India

Telephone +91 (22) 4345 5300  
Fax +91 (22) 4345 5399

## Limited review report on unaudited Quarterly Standalone Financial Results and standalone year-to-date results of RPG Life Sciences Limited under Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

### The Board of Directors of RPG Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 30 September 2019 and the year to date results for the period from 1 April 2019 to 30 September 2019 ('the Statement').
2. This Statement, which is the responsibility of the Company's management and which is approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BSR & Co. LLP  
Chartered Accountants  
Firm's Registration No: 101248W/W - 100022

*B. H. Dhupelia*

Bhavesh Dhupelia  
Partner

Membership No: 042070  
UDIN: 19042070AAAACY7827

Mumbai  
30 October 2019

(Rs. in Lakhs)

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2019**


Particulars	Quarter ended			Six months ended		Year ended
	30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1 Revenue from Operations</b>	9,849	9,404	9,050	19,253	17,039	33,016
<b>2 Other Income</b>	15	16	6	31	45	80
<b>3 Total Income</b>	<b>9,864</b>	<b>9,420</b>	<b>9,056</b>	<b>19,284</b>	<b>17,084</b>	<b>33,096</b>
<b>4 Expenses</b>						
(a) Cost of Materials Consumed	1,746	1,677	1,194	3,423	2,705	5,117
(b) Purchases of Stock-in-Trade	1,951	1,134	957	3,085	2,172	4,516
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock in-Trade	(436)	462	1,126	26	876	1,371
(d) Employee Benefits Expense	2,493	2,312	2,386	4,805	4,608	8,993
(e) Finance Costs	36	73	105	109	209	399
(f) Depreciation and Amortisation Expense	416	392	381	808	752	1,532
(g) Other Expenses	2,454	2,284	2,597	4,738	5,194	9,663
<b>Total Expenses</b>	<b>8,660</b>	<b>8,334</b>	<b>8,746</b>	<b>16,994</b>	<b>16,516</b>	<b>31,591</b>
<b>5 Profit before tax</b>	<b>1,204</b>	<b>1,086</b>	<b>310</b>	<b>2,290</b>	<b>568</b>	<b>1,505</b>
<b>6 Income tax expenses</b>						
a. Current Tax	321	300	85	621	146	284
b. Deferred Tax	(94)	(49)	9	(143)	23	140
<b>7 Profit for the period</b>	<b>977</b>	<b>835</b>	<b>216</b>	<b>1,812</b>	<b>399</b>	<b>1,081</b>
<b>8 Other Comprehensive Income</b>						
(i) Items that will not be reclassified to Profit or Loss	(10)	(10)	(6)	(20)	(12)	(41)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	3	3	2	6	4	14
<b>Other Comprehensive Income Net of Tax</b>	<b>(7)</b>	<b>(7)</b>	<b>(4)</b>	<b>(14)</b>	<b>(8)</b>	<b>(27)</b>
<b>9 Total Comprehensive Income for the period</b>	<b>970</b>	<b>828</b>	<b>212</b>	<b>1,798</b>	<b>391</b>	<b>1,054</b>
<b>10 Paid-up Equity Share Capital</b> (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
<b>11 Other Equity</b>						14,727
<b>12 Earnings per Share (of Rs. 8/- each) (not annualised):</b>						
(a) Basic	5.91	5.05	1.31	10.96	2.41	6.54
(b) Diluted	5.91	5.05	1.31	10.96	2.41	6.54

**Notes:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 30, 2019. The Statutory Auditors of the Company have conducted a 'Limited Review' of the results for the quarter and six months ended September 30, 2019.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- Effective April 1, 2019 the Company has adopted Ind AS 116 "Leases" using the modified retrospective approach. This has resulted in recognising right of use assets and lease liability as on April 1, 2019. The adoption of the standard did not have any material impact on the financial results.



For RPG Life Sciences Limited

  
 Yugal Sikri

Managing Director  
 Mumbai, October 30, 2019

**Standalone unaudited balance sheet as at September 30, 2019**

(Rs. in Lakhs)

Particulars	As at 30 September 2019	As at 31 March 2019
	(Unaudited)	(Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	8,722	8,251
Capital work-in-progress	511	1,012
Other intangible assets	4,241	4,513
Intangible assets under development	780	705
Financial assets		
i. Loans	17	10
ii. Other financial assets	25	30
Deferred tax assets (Net)	505	618
Current Tax asset (Net)	95	125
Other non-current assets	111	151
<b>Total non-current assets</b>	<b>15,007</b>	<b>15,415</b>
<b>Current assets</b>		
Inventories	4,162	4,104
Financial assets		
i. Trade receivables	5,702	3,890
ii. Cash and cash equivalents	39	37
iii. Bank balances other than (ii) above	47	40
iv. Other financial assets	108	96
Other current assets	1,542	1,542
<b>Total current assets</b>	<b>11,600</b>	<b>9,709</b>
<b>Total assets</b>	<b>26,607</b>	<b>25,124</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,323	1,323
Other equity	16,046	14,727
<b>Total equity</b>	<b>17,369</b>	<b>16,050</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
i. Borrowings	333	658
ii. Other financial liabilities	326	299
Provisions	335	335
<b>Total non-current liabilities</b>	<b>994</b>	<b>1,292</b>
<b>Current liabilities</b>		
Financial liabilities		
i. Borrowings	795	2,904
ii. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	152	-
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	4,643	2,513
iii. Other financial liabilities	897	823
Provisions	1,126	1,033
Current tax liabilities (Net)	53	-
Other current liabilities	578	509
<b>Total current liabilities</b>	<b>8,244</b>	<b>7,782</b>
<b>Total liabilities</b>	<b>9,238</b>	<b>9,074</b>
<b>Total equity and liabilities</b>	<b>26,607</b>	<b>25,124</b>



**Standalone unaudited statement of cash flows for the six months ended September 30, 2019**

(Rs. in Lakhs)

Particulars	For the period ended 30 September 2019	For the period ended 30 September 2018	For the year ended 31 March 2019
	Unaudited	Unaudited	Audited
<b>A Cash Flow from operating activities</b>			
<b>Profit before income tax</b>	<b>2,290</b>	568	1,505
Adjustments for			
<b>Add:</b>			
Depreciation and amortisation expenses	<b>808</b>	752	1,532
Finance costs	<b>109</b>	209	399
Loss on disposal of property, plant and equipment	<b>(2)</b>	3	6
Unrealised exchange rate difference	<b>(9)</b>	(39)	25
Provision for Doubtful Debts and Advances (Net)	-	53	60
Interest received	<b>(16)</b>	(4)	(12)
Provisions no longer required and written back	<b>(4)</b>	(2)	(2)
	<b>3,176</b>	1,540	3,513
<b>Working capital adjustments:</b>			
(Increase) / Decrease in trade receivables	<b>(1,800)</b>	868	2,860
(Increase) in financial assets - Loans	<b>(2)</b>	(1)	(3)
Decrease in other non-current assets	-	-	6
(Increase) in other financial assets	<b>(12)</b>	(21)	(8)
Decrease in other current assets	-	416	334
(Increase) / Decrease in inventories	<b>(58)</b>	683	1,265
Increase / (Decrease) in trade payables	<b>2,282</b>	(1,682)	(2,673)
Increase / (Decrease) in other financial liabilities	<b>64</b>	(373)	(332)
Increase / (Decrease) in provisions	<b>109</b>	(78)	(177)
Increase in other current liabilities	<b>69</b>	108	165
<b>Cash generated from operations</b>	<b>3,828</b>	1,460	4,950
Income taxes paid	<b>(314)</b>	(120)	(372)
<b>Net cash inflow from operating activities</b>	<b>3,514</b>	1,340	4,578
<b>B Cash flow from investing activities:</b>			
Acquisition of property, plant and equipment and Intangible assets	<b>(733)</b>	(526)	(1,968)
Proceeds from sale of property, plant and equipment and Intangible	7	4	11
Bank deposits - (Repaid)/Received	<b>(7)</b>	45	43
Interest received	<b>16</b>	4	12
<b>Net cash (outflow) from investing activities</b>	<b>(717)</b>	(473)	(1,902)
<b>C Cash flow from financing activities</b>			
Proceeds from long term borrowings	-	-	311
Repayment of long term borrowings	<b>(44)</b>	(296)	(1,195)
(Repayment of) / Proceeds from Short-term Borrowings (Net)	<b>(2,174)</b>	144	(888)
Dividend paid including dividend distribution tax thereon	<b>(479)</b>	(479)	(479)
Interest paid	<b>(98)</b>	(195)	(399)
<b>Net cash (outflow) from financing activities</b>	<b>(2,795)</b>	(826)	(2,650)
<b>Net increase in cash and cash equivalents</b>	<b>2</b>	41	26
Add: Cash and cash equivalents at the beginning of the financial year	<b>37</b>	11	11
<b>Cash and cash equivalents at the end of the period / year</b>	<b>39</b>	52	37
<b>Cash Flow statement as per above comprises of the following</b>			
Cash and cash equivalents	<b>39</b>	52	37
	<b>39</b>	52	37

